Recall Database
Teva Pharmaceuticals Usa Recalls
An assortment of pharmaceutical pills (representative file photo). Specific recalled product: see recall details below. Photo: Michael Nutt / Wikimedia Commons (CC BY-SA 2.0).
- Recalls in database
- 18
- Agency
- FDA
- Years covered
- 2025–2026
Teva Pharmaceuticals USA has 18 records, all FDA recalls. They span several of the site's taxonomy classes — the largest group is drug or medical-product contamination — with the rest distributed across other classifications. The notices run from 2025 through 2026.
This is an FDA-only hub. Use it to look up a recalled Teva medication by lot. Each row links to the FDA enforcement record with the recall classification and the firm's corrective action.
How this hub is built. This page collects the 18 recall records tied to Teva Pharmaceuticals Usa in the current 411 Press recall dataset. Records are grouped by a normalized version of the recalling firm's name (normalizer version 2026-07-28.C3.2). Parent, subsidiary, and "doing business as" relationships are not merged unless the agency data states them, so a corporate family can appear under more than one name. Regulator for these records: FDA. They were published 2025–2026. A recall count reflects how much recall activity fell inside the ingestion window — roughly February 2023 through May 2026, refreshed late May 2026 — not a ranking of relative safety. Larger manufacturers and higher-volume product lines file more notices. This is the current dataset, not an all-time total, and it grows as new notices are ingested. Every row links to the original agency notice.
2026 (14)
- Class II
Octreotide Acetate for Injectable Suspension
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
- Class II
Claravis (isotretinoin capsule
Failed Impurities/Degradation Specifications: Out of specification for specific impurity Tretinoin
- Class II
Clonidine Transdermal System
CGMP Deviations: use of an unapproved raw material
- Class II
Clonidine Transdermal System
CGMP Deviations: use of an unapproved raw material
- Class II
Clonidine Transdermal System
CGMP Deviations: use of an unapproved raw material
- Class II
Octreotide Acetate for Injectable Suspension
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
- Class II
Octreotide Acetate for Injectable Suspension
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
- Class II
Octreotide Acetate for Injectable Suspension
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
- Class II
Metoprolol Succinate Extended-Release Tablets
Failed Dissolution Specifications
- Class II
Metoprolol Succinate Extended-Release Tablets
Failed Dissolution Specifications
- Class II
Metoprolol Succinate Extended-Release Tablets
Failed Dissolution Specifications
- Class II
Metoprolol Succinate Extended-Release Tablets
Failed Dissolution Specifications
- Class II
Isotretinoin Capsules
Superpotent and Subpotent
- Class II
Isotretinoin Capsules
Superpotent and Subpotent
2025 (4)
- Class III
Carton label: Testosterone Gel 1%
Defective Container - A defect in the side-seal which allows leakage of product.
- Class II
Amoxicillin and Clavulanate Potassium for Oral Suspension USP
Subpotent drug; Clavulanate Potassium component
- Class II
Prazosin Hydrochloride
CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots.
- Class II
Prazosin Hydrochloride
CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots.